Recombinant PCSK9 anticorps

N° du produit ABIN7321660

Détail du produit anti-PCSK9 anticorps

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Lapin

Clonalité: Monoclonal

Conjugué: Cet anticorp PCSK9 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Réactivité croisée: Humain

Purification: Affinity-chromatography

Immunogène: A synthesized peptide derived from human PCSK9

Clone: 7F2

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: WB:1:500-1:5000, IHC:1:50-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur PCSK9

Antigène: PCSK9 (Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9))

Autre désignation: PCSK9 (PCSK9 Produits)

Synonymes: anticorps FH3, anticorps HCHOLA3, anticorps LDLCQ1, anticorps NARC-1, anticorps NARC1, anticorps PC9, anticorps AI415265, anticorps AI747682, anticorps Narc1, anticorps proprotein convertase subtilisin/kexin type 9, anticorps proprotein convertase subtilisin/kexin type 9 L homeolog, anticorps PCSK9, anticorps pcsk9.L, anticorps pcsk9, anticorps Pcsk9

Sujet:

Background: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Aliases: Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9), PCSK9, NARC1

UniProt: Q8NBP7